Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence

Movement Disorders

Volumn 17, Issue 1, 2002, Pages 13-19

  Obinu, Maria C ^a   Reibaud, Michel ^a   Blanchard, Véronique ^a   Moussaoui, Saliha ^a   Imperato, Assunta ^a  

^a SANOFI   (France)

Author keywords

Locomotor impairment; MPTP; Neurological deficit; Neuronal loss; Neuroprotection; Riluzole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NEUROPROTECTIVE AGENT; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL PROTECTION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ENERGY CONSUMPTION; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MARMOSET; MEDICAL ASSESSMENT; MOTOR PERFORMANCE; NERVOUS SYSTEM FUNCTION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NISSL STAINING; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PUTAMEN; REVIEW; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; NISSL SUBSTANCE; PATHOLOGY; RANDOMIZATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CALLITHRIX; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; FEMALE; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; NEUROPROTECTIVE AGENTS; NISSL BODIES; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RANDOM ALLOCATION; RILUZOLE; SUBSTANTIA NIGRA;

EID: 0036368298     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1272     Document Type: Review

References (41)

1. Sutcliffe RLG, Meara JR. Parkinson's disease epidemiology in the Northamptom District, England. Acta Neurol Scand 1995;92:443-450.
2. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A. Prevalence of Parkinson's disease in the elderly: The Rotterdam Study. Neurology 1995;45:2143-2146.
3. Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, Oertel WH. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995;52: 1017-1022.
4. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.
5. + channels in myelinated nerve fibre. Pfügers Arch 1991;419:603-609.
6. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel α subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-1060.
7. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47(Suppl 4):s223-s232.
8. Mantz J. Riluzole. Drug Rev 1996;2:40-51.
9. Meininger V. Efficacy of riluzole in the treatment of amyotrophic lateral sclerosis. Rev Contemp Pharmacother 1997;8:255-263.
10. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992;147:209-212.
11. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993;250:473-476.
12. Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand JJ, Gueremy C, Le Fur G. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acids neurotransmission-II. Biochemical properties. Neuropharmacology 1985;24:1085-1092.
13. Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
14. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330: 585-591.
15. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
16. Pratt J, Rataud J, Bardot F, Roux M, Blanchard JC, Laduron PM, Stutzmann JM. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett 1992; 140:225-230.
17. Wahl F, Allix M, Plotkine M, Boulu RG. Effect of riluzole on focal cerebral ischemia in rats. Eur J Pharmacol 1993;230:209-214.
18. Stutzmann JM, Pratt J, Boraud T, Gross C. The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport 1996; 7:387-392.
19. Wahl F, Renou E, Mary V, Stutzmann JM. Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury. Brain Res 1997;756:247-255.
20. Mary V, Wahl F, Stutzmann JM. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic transmission. Neurosci Lett 1995;201:92-96.
21. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole, and gabapentin in transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
22. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 1997;152(Suppl 1):S67-S73.
23. Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998;50:62-66.
24. Boireau A, Dubedat P, Bordier F, Peny C, Miquet JM, Durand G, Meunier M, Doble A. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 1994;5:2657-2660.
25. +-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport 1994;5:2157-2160.
26. Barneoud P, Mazadier M, Miquet JM, Parmentier S, Dubedat P, Doble A, Boireau A. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 1996;4:971-983.
27. Bezard E, Stutzmann JM, Imbert C, Boraud T, Boireau A, Gross CE. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol 1998; 356:101-104.
28. Kim JJ, Rison RA, Fanselow MS. Effects of amygdala, hippocampus, and periaqueductal gray lesions on short-and long-term contextual fear. Behav Neurosci 1993;107:1093-1098.
29. Fanselow MS, DeCola JP, Young SL. Mechanisms responsible for reduced contextual conditioning with massed unsignaled unconditional stimuli. J Exp Physiol 1993;19:121-137.
30. Pearce RK, Collins P, Jenner P, Emmett C, Marsden CD. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset. Synapse 1996;23:192-200.
31. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
32. Herrero MT, Hirsch EC, Kastner A, Ruberg M, Luquin MR, Laguna J, Javoy-Agid F, Obeso JA, Agid Y. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 1993;56:499-511.
33. Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M, Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/b1 and CD-1 mice. Exp Neurol 1994; 126:195-204.
34. Stephan H, Baron G, Schwerdtfeger WK. The brain of the common marmosets (Callithrix jacchus). Berlin: Springer-Verlag; 1980.
35. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995;284:299-307.
36. + accumulation. Neuropharmacology 2000; 39:1016-1020.
37. Pifl C, Schingnitz G, Hornykiewicz O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett 1988;92:228-233.
38. Hornykiewicz O, Pifl C, Schingnitz G, et al. The cause of Parkinson's disease: MPTP, ageing and the striatal dopamine loss. In: Nappi G, et al., editors. Neurodegenerative disorders: the role played by endotoxins and xenobiotics. New York: Raven Press; 1988.
39. Trounce I, Byrne E, Marzuki S. Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in aging. Lancet 1989;1:637-639.
40. Cooper JM, Mann VM, Schapira AHV. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of aging. J Neurol Sci 1992;113:91-98.
41. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44:S175-S188.